15 September 2016
Dechra Pharmaceuticals PLC
(the Company)
Director Shareholding
The Company announces that on 14 September 2016 the following Directors were granted awards over ordinary shares of 1 pence each in the Company in connection with the Dechra Long Term Incentive Plan 2008 (the Plan):
Name of individual |
Director |
Type of award |
Number of shares subject to award |
Ian Page |
Director |
LTIP Award - nil cost option |
73,667 |
Tony Griffin |
Director |
LTIP Award - Conditional award |
20,858 |
The vesting of all the above awards is subject to the achievement of performance targets. In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period. Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance measure. If the ROCE performance condition is not met, then the LTIP options will lapse in full.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
||
a) |
Name |
Ian Page
|
|
2. |
Reason for the notification |
||
a) |
Position/status |
Director
|
|
b) |
Initial notification/ amendment |
Initial Notification |
|
3. |
Details of the Issuer |
||
a) |
Name |
Dechra Pharmaceuticals PLC |
|
b) |
LEI code |
N/A |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 1 pence each
ISIN: GB0009633180 |
|
b) |
Nature of the transaction |
Grant of nil cost options under the Company's Long Term Incentive Plan |
|
c) |
Price(s) and volumes(s) |
Price(s) Nil cost |
Volume(s) 73,637 |
d) |
Aggregated information - Aggregate volume - Price |
N/A |
|
e) |
Date of the transaction |
2016.09.14 |
|
f) |
Place of the transaction |
Outside a trading venue |
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
||
a) |
Name |
Tony Griffin
|
|
2. |
Reason for the notification |
||
a) |
Position/status |
Director
|
|
b) |
Initial notification/ amendment |
Initial Notification |
|
3. |
Details of the Issuer |
||
a) |
Name |
Dechra Pharmaceuticals PLC |
|
b) |
LEI code |
N/A |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 1 pence each
ISIN: GB009633180 |
|
b) |
Nature of the transaction |
Grant of a conditional award under the Company's Long Term Incentive Plan |
|
c) |
Price(s) and volumes(s) |
Price(s) Nil cost |
Volume(s) 20,858 |
d) |
Aggregated information - Aggregate volume - Price |
N/A |
|
e) |
Date of the transaction |
2016.09.14 |
|
f) |
Place of the transaction |
Outside a trading venue |
For further information, please contact:
Suzana Cross, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.